Arcutis Biotherapeutics Files 10-Q/A Amendment
Ticker: ARQT · Form: 10-Q/A · Filed: Jul 24, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 10-Q/A |
| Filed Date | Jul 24, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q/A, amendment, financial-reporting
TL;DR
Arcutis Biotherapeutics filed an amendment to their Q1 2024 10-Q. Check for updates.
AI Summary
Arcutis Biotherapeutics, Inc. filed an amendment (Amendment No. 1) to its Form 10-Q for the quarterly period ended March 31, 2024. This filing, dated July 24, 2024, provides updated information for the period. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates an update or correction to Arcutis Biotherapeutics' quarterly financial reporting, which is crucial for investors to have the most accurate and up-to-date information.
Risk Assessment
Risk Level: low — This is a routine amendment to a quarterly report, not indicative of new material risks.
Key Numbers
- 20240331 — Quarter End Date (The reporting period for the 10-Q/A filing.)
- 20240724 — Filing Date (The date the amendment was submitted to the SEC.)
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- March 31, 2024 (date) — Quarterly period end date
- July 24, 2024 (date) — Filing date
- 001-39186 (identifier) — SEC File Number
FAQ
What specific information is being amended in the 10-Q filing?
The filing is an amendment (Amendment No. 1) to the Form 10-Q for the quarterly period ended March 31, 2024. Specific details of the amendments are not provided in this header information.
What is the SEC file number for Arcutis Biotherapeutics?
The SEC file number for Arcutis Biotherapeutics, Inc. is 001-39186.
When was the original quarterly period reported on?
The quarterly period reported on ended on March 31, 2024.
What is the fiscal year end for Arcutis Biotherapeutics?
The fiscal year end for Arcutis Biotherapeutics is December 31.
In which state is Arcutis Biotherapeutics incorporated?
Arcutis Biotherapeutics, Inc. is incorporated in Delaware.
Filing Stats: 1,296 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2024-07-24 16:10:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 ARQT The Nasdaq Global Select Marke
Filing Documents
- d691902d10qa.htm (10-Q/A) — 54KB
- d691902dex311.htm (EX-31.1) — 5KB
- d691902dex312.htm (EX-31.2) — 5KB
- 0001193125-24-183778.txt ( ) — 240KB
- arqt-20240331.xsd (EX-101.SCH) — 4KB
- arqt-20240331_cal.xml (EX-101.CAL) — 1KB
- arqt-20240331_def.xml (EX-101.DEF) — 14KB
- arqt-20240331_lab.xml (EX-101.LAB) — 19KB
- arqt-20240331_pre.xml (EX-101.PRE) — 15KB
- d691902d10qa_htm.xml (XML) — 6KB
OTHER INFORMATION
PART II. OTHER INFORMATION Item5. OTHER INFORMATION Trading Plans During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K, except as follows: On March 5, 2024, Howard G. Welgus, M.D., member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 93,386 shares of common stock held by Mr. Welgus and the potential exercise and sale of up to 26,614 options held by Mr. Welgus between June 4, 2024 and May 30, 2025. ITEM6. EXHIBITS Exhibit Number Description of Document Incorporated by Reference Form Date Number Filed/ Furnished Herewith 3.1 Restated Certificate of Incorporation. 10-Q 5/12/20 3.1 3.2 Restated Bylaws. 10-Q 5/12/20 3.2 4.1 Form of Common Stock Certificate. S-1/A 1/21/20 4.1 4.2^ Amended and Restated Investors' Rights Agreement, dated October 8, 2019, by and among the Registrant and certain of its stockholders. S-1/A 1/21/20 4.2 10.1 Amended and Restated Sales Agreement, dated January 31, 2024, by and between Registrant and Cowen and Company, LLC. S-3 1/31/24 1.2 10.2 Amendment Employment Agreement, dated February 22, 2024, by and between the Registrant and Matthew R. Moore. 10-K 2/22/24 10.35 10.3 License Agreement, dated as of February 27, 2024, by and between the Registrant and Sato Pharmaceutical Co., Ltd. 10-Q 5/14/24 10.3 10.4 First Amendment to the License Agreement, dated February 18, 2024, by and between the Registrant and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 10-Q 5/14/24 10.4 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: July 24, 2024 By: /s/ Todd Franklin Watanabe Todd Franklin Watanabe President, Chief Executive Officer and Director (Principal Executive Officer) Date: July 24, 2024 By: /s/ David Topper David Topper Chief Financial Officer (Principal Financial and Accounting Officer)